News

In Certain CTEPH Patients, Vascular Remodeling May Lead to Hypoxemia

Patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are successfully treated with pulmonary endarterectomy (PEA) may be at increased risk of having low levels of oxygen in the blood due to severe pulmonary arteriopathy, a condition characterized by pulmonary artery remodeling, according to a study from Chiba University in Japan. The…

Symple Surgical Partners to Advance Hypertension Therapy Called Microwave Ablation

Symple Surgical (SSI), a start-up medical device company, announced that it has entered into a development agreement with a confidential partner to advance its microwave ablation technology, for the treatment of hypertension and potentially other conditions, including pulmonary hypertension. The unnamed partner, it said in a press release, has with a long-standing market leadership…

High-Fat Diet in Diabetic Moms May Add to Risk of Pulmonary Hypertension in Newborn

Children born to women with late-stage gestational diabetes — caused by a pregnancy-related, transient increase in blood sugar levels (hyperglycemia) — or to women who are overweight or obese are known to be a higher risk of pulmonary complications, namely respiratory distress and persistent pulmonary hypertension of the newborn (PPHN). While efforts to…

2 Possible New Treatments for Pulmonary Hypertension ID’d in Study

Researchers identified two new drugs, both signaling inhibitors, that could aid in the treatment of pulmonary hypertension (PH) by altering vessel stiffness and its downstream control of metabolism. Their work also suggests that a previously unknown link exists between vessel hardening and energy production in the disease. The study, “Vascular…

Karos Reports Positive Safety Data from Phase 1 Trials of PAH Therapy

Karos Pharmaceuticals, a start-up focused on the selective modulation of peripheral serotonin synthesis, recently reported positive results from its Phase 1 clinical trials evaluating KAR5585, a compound being developed to treat orphan diseases such as pulmonary arterial hypertension (PAH) and carcinoid syndrome. KAR5585 is a first-in-class, selective inhibitor of tryptophan hydroxylase…